Cengent Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

  • Investments
  • 1

Cengent Therapeutics General Information

Description

Operator of a drug discovery company. The company provides a suite of services and capabilities to optimize the drug discovery process and provides technologies such as homology modeling, X-ray crystallography and nuclear magnetic resonance (NMR) .

Contact Information

Formerly Known As
Structural Bioinformatics
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 10929 Technology Place
  • San Diego, CA 92127
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 10929 Technology Place
  • San Diego, CA 92127
  • United States
+1 (858)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cengent Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cengent Therapeutics‘s full profile, request access.

Request a free trial

Cengent Therapeutics Patents

Cengent Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080070867-A1 3-[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-4-(4-methanesulfonyl-phenyl)-2-oxo-2,3-dihydro-imidazole-1-carboxylic acid ethyl ester; diabetes, kidney failure, atherosclerosis, neurodegenerative diseases , obesity, cancer Inactive 19-Jan-2005
US-7381736-B2 N-(4-{2-[[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid; antidiabetic, hypotensive agent; ischemia, kidney failure, atherosclerosis, metabolic syndrome, insulin resistance, leptin resistance, obesity, neurodegenerative diseases Inactive 02-Sep-2004
US-20060194768-A1 N-(4-{2-[[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid; antidiabetic, hypotensive agent; ischemia, kidney failure, atherosclerosis, metabolic syndrome, insulin resistance, leptin resistance, obesity, neurodegenerative diseases Active 02-Sep-2004
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases Inactive 09-Jul-2004
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases Inactive 17-Jun-2004 A61K31/66
To view Cengent Therapeutics’s complete patent history, request access »

Cengent Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cengent Therapeutics‘s full profile, request access.

Request a free trial

Cengent Therapeutics Acquisitions (1)

Cengent Therapeutics’s most recent deal was a Merger/Acquisition with GeneFormatics. The deal was made on 19-May-2003.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GeneFormatics 19-May-2003 Merger/Acquisition Biotechnology
To view Cengent Therapeutics’s complete acquisitions history, request access »

Cengent Therapeutics FAQs

  • When was Cengent Therapeutics founded?

    Cengent Therapeutics was founded in 2003.

  • Where is Cengent Therapeutics headquartered?

    Cengent Therapeutics is headquartered in San Diego, CA.

  • What industry is Cengent Therapeutics in?

    Cengent Therapeutics’s primary industry is Drug Discovery.

  • Is Cengent Therapeutics a private or public company?

    Cengent Therapeutics is a Private company.

  • What is Cengent Therapeutics’s current revenue?

    The current revenue for Cengent Therapeutics is .

  • Who are Cengent Therapeutics’s investors?

    Aisling Capital, Burrill & Co, DKA Capital, IngleWood Ventures, and Ironbark Asset Management Fund Services are 5 of 10 investors who have invested in Cengent Therapeutics.

  • When was Cengent Therapeutics acquired?

    Cengent Therapeutics was acquired on 27-Jun-2006.

  • Who acquired Cengent Therapeutics?

    Cengent Therapeutics was acquired by Metabasis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »